Roivant Sciences Ltd. (NASDAQ:ROIV) and its subsidiary Priovant Therapeutics announced positive results Wednesday from two Phase 3 trials evaluating brepocitinib for noninfectious uveitis (NIU), an inflammatory eye disease that can cause permanent vision loss.
The investigational therapy achieved its primary endpoint across both the CLARITY-1 and CLARITY-2 studies while showing statistically significant improvements across all key secondary measures, even with a strict steroid-reduction schedule.
The company’s Lisraya (brepocitinib) is the first and only targeted oral therapy approved for the treatment of adults with dermatomyositis.
Understanding The Impact Of Noninfectious Uveitis
NIU represents a severe inflammatory eye condition and ranks among the leading drivers of blindness in working-age individuals.
Without sufficient treatment, the condition triggers permanent sight loss alongside eye pain, floaters, and extensive visual deficits affecting clarity, color perception, night vision, and peripheral focus.
These symptoms disrupt essential daily tasks such as reading, driving, working, and self-care for roughly 70,000 to 190,000 American adults.
CLARITY Trial Efficacy Findings
Brepocitinib consistently lowered the rate of treatment failure across several patient groups, covering intermediate, posterior, and panuveitis, as well as participants with or without previous TNFi therapy.
The drug also demonstrated efficacy across underlying conditions such as sarcoidosis, birdshot chorioretinopathy, and idiopathic cases.
Secondary endpoints revealed sustained steroid-free quiescence at Week 48, resolved macular edema, improved chorioretinal vascular leakage verified through wide-field fluorescein angiography, and elevated visual functioning scores on the NEI VFQ-25 questionnaire.
Tolerability Profile And Regulatory Plans
Patients tolerated brepocitinib well throughout the studies. Most adverse events remained mild to moderate, and adverse events prompted treatment discontinuation in just 3% of trial participants.
The trials revealed no new safety signals, aligning with the drug’s established profile. Priovant plans to submit a supplemental New Drug Application for brepocitinib in NIU during the first half of 2027.
ROIV Price Action: Roivant Sciences shares were up 4.30% at $36.42 at the time of publication on Wednesday, according to Benzinga Pro data.
Photo by T. Schneider via Shutterstock
